- Chayama K, Saito S, Arase Y, Ikeda K, Matsumoto T, Sakai Y, et al. Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C. Hepatology 1991; 13: 1040–3.
- Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, et al. The Hepatitis Interventional Therapy Group. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomised, controlled trial. N Engl J Med 1989; 321: 1501–6.
- Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant interferon alfa therapy for chronic hepatitis C. N Engl J Med 1989; 321: 1506–10.
- Hagiwara H, Hayashi N, Mita E, Takehara T, Kasahara A, Fusamoto H, et al. Quantative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterol 1993; 104: 877–83.
- Lau JYN, Davis GL, Kniffen J, Qian K, Urdea MS, Chan CS, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341: 1501–4.
- Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22: 1050–6.
- Yoshioka K, Kakumi S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-a therapy: relationship to genotypes of hepatitis C virus. Hepatology 1992; 16: 293–9.
- Cooksley WGE. Interferon treatment of chronic hepatitis C with cirrhosis. J Viral Hep 1997; 4 Suppl. 1: 85–8.
- Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. J Clin Invest 1995; 96: 224–30.
- Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77–81.
- Jouët P, Roudot-thoraval F, Dhumeaux D, Metreau J. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Gastroenterol 1994; 106: 686–90.
- Saito T, Shinzawa H, Kuboki M, Ishibashi M, Toda H, Okuyama Y, et al. A randomised controlled trial of human lymphoblastoid interferon in patients with compensated type C cirrhosis. Am J Gastroenterol 1994; 89: 681–6.
- Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferon-a on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051–5.
- Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797–801.
- Ide T, Sata M, Suzuku H, Murashima S, Miyajima I, Shirachi M, et al. Evaluation of interferon treatment in cirrhotic patients with hepatitis C. Kansenshogaku Zasshi 1996; 70: 597–604.
- Okamoto H, Okada S, Sugiyama Y, Tanaka T, Sugai Y, Akahane Y, et al. Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 5′-noncoding region. Jpn J Exp Med 1990; 60: 215–22.
- Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, et al. Typing hepatitis C virus by polymerase chain reaction with type specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73: 673–9.
- Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993; 74: 2391–9.
- Davis GL, Lau JY, Urdea MS, Neuwald PD, Wilber JC, Lindsay K, et al. Quantative detection of hepatitis C virus RNA with a solid-phase signal amplification method: definition of optimal conditions for specimen collection and clinical application in interferon-treated patients. Hepatology 1994; 19: 1337 – 41.
- Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, et al. Molecular cloning of human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA 1990; 87: 9524–8.
- Okamoto H, Kojima M, Okada S, Yoshizawa H, Iizuka H, Tanaka T, et al. Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. Virology 1992; 190: 894–9.
- Tanaka T, Kato N, Nakagawa M, Ootsuyama Y, Cho M, Nakazawa T, et al. Molecular cloning of hepatitis C virus genome from a single Japanese carrier: sequence variation within the same individual and among infected individuals. Virus Res 1992; 23: 39–53.
- Kuwana K, Ichida T, Kamimura T, Ohkoshi S, Ogata N, Harada T, et al. Risk factors and effect of interferon therapy in the development of hepatocellular carcinoma: a multivariate analysis in 343 patients. J Gastroenterol Hepatol 1997; 12: 149–55.
- Miyajima I, Sata M, Gondo K, Suzuki H, Tanikawa K. Interferon accumulation in cirrhotic rat liver. J Viral Hep 1996; 3: 23–7.
- Ishimura N, Fukuda R, Fukumoto S. Relationship between the intrahepatic expression of interferon-α receptor mRNA and the histological progress of hepatitis C virus-associated chronic liver disease. J Gastroenterol Hepatol 1996; 11: 712–7.
- Chayama K, Tsubota A, Kobayashi M, Okamoto K, Hashimoto M, Miyano Y, et al. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology 1997; 25: 745–9.
- Kurosaki M, Enomoto N, Murakami T, Sakuma I, Asahina Y, Yamamoto C, et al. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to Interferon-β therapy. Hepatology 1997; 25: 750–3.
- Zeuzem S, Lee J, Roth WK. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa. Hepatology 1997; 25: 740–4.
- Squadrito G, Leone F, Sartori M, Nalpas B, Berthelot P, Raimondo G, et al. Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. Gastroenterol 1997; 113: 567–72.
- Khorsi H, Castelain S, Wyseur A, Izopet J, Canva V, Rombout A, et al. Mutations of hepatitis C virus 1b NS5A 2209–2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients. J Hepatol 1997; 27: 72–7.
- Hofgartner WT, Polyak SJ, Sullivan DG, Carithers RL, Gretch DR. Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV Genotype 1a or 1b. J Med Virol 1997; 53: 118–26.
- Odeberg J, Yun Z, Sönnerborg A, Weiland O, Lundeberg J. Variation in the hepatitis C virus NS5a region in relation to hypervariable region 1 heterogeneity during interferon treatment. J Med Virol 1998; 56: 33–8.
- Sato C, Enomoto N. Mutations in the NS5A region of HCV and interferon efficacy. Gastroenterol 1998; 115: 796.
- Herion D, Hoofnagle JH. The interferon sensitivity determining region: All hepatitis C virus isolates are not the same. Hepatology. 1997; 25: 769–71.
- Almarri A, El Dwick N, Al Kabi S, Sleem K, Rashed A, Ritter MA, et al. Interferon-alpha therapy in HCV hepatitis: HLA phenotype and cirrhosis are independent predictors of clinical outcome. Hum Immunol. 1998; 59: 239–42.
- Kato N, Lan KH, Ono-nita SK, Shiratori Y, Omata M. Hepatitis C virus nonstructural region 5A protein is a potent transcriptional activator. J Virol 1997; 71: 8856–9.
- Gale MJ, Korth MJ, Tang NM, Tan S, Hopkins DA, Dever TE, et al. Evidence that hepatitis C virus resistence to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997; 230: 217–27.
Mutations in the NS5A Gene Predict Response to Interferon Therapy in Japanese Patients with Chronic Hepatitis C and Cirrhosis
Reprints and Corporate Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Academic Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.